Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial

American Heart Journal

Volumn 179, Issue , 2016, Pages 59-68

  Ezekowitz, Michael D ^a,b   Pollack, Charles V ^c   Sanders, Paul ^d   Halperin, Jonathan L ^e   Spahr, Judith ^b   Cater, Nilo ^f   Petkun, William ^g   Breazna, Andrei ^f   Kirchhof, Paulus ^h,i   Oldgren, Jonas ^j  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f PFIZER INC   (United States)

^g BRISTOL MYERS SQUIBB   (United States)

^h UNIVERSITY OF BIRMINGHAM   (United Kingdom)

ⁱ UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^j UPPSALA UNIVERSITY   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; APIXABAN; CREATININE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; EMBOLISM; FEMALE; FOLLOW UP; HEART ATRIUM THROMBOSIS; HOSPITALIZATION; HUMAN; INCIDENCE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TREATMENT OUTCOME; VERY ELDERLY; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; COMPLICATION; STROKE;

ANTICOAGULANTS; ATRIAL FIBRILLATION; DRUG THERAPY, COMBINATION; ELECTRIC COUNTERSHOCK; FACTOR XA INHIBITORS; HEMORRHAGE; HEPARIN; HUMANS; PYRAZOLES; PYRIDONES; STROKE; WARFARIN;

EID: 84978173368     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2016.06.008     Document Type: Article

References (25)

1. [1] Lloyd-Jones, D.M., Wang, T.J., Leip, E.P., et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 110 (2004), 1042–1046.
2. [2] January, C.T., Wann, L.S., Alpert, J.S., et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol 64 (2014), e1–e76.
3. [3] Arnold, A.Z., Mick, M.J., Mazurek, R.P., et al. Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter. J Am Coll Cardiol 19 (1992), 851–855.
4. [4] Weinberg, D.M., Mancini, J., Anticoagulation for cardioversion of atrial fibrillation. Am J Cardiol 63 (1989), 745–746.
5. [5] Bjerkelund, C.J., Orning, O.M., The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation. Am J Cardiol 23 (1969), 208–216.
6. [6] Klein, A.L., Grimm, R.A., Murray, D., et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 344 (2001), 1411–1420.
7. [7] Nagarakanti, R., Ezekowitz, M.D., Oldgren, J., et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 123 (2011), 131–136.
8. [8] Camm, A.J., Lip, G.Y., De Caterina, R., et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33 (2012), 2719–2747.
9. [9] You, J.J., Singer, D.E., Howard, P.A., et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141:2 Suppl. (2012), e531S–e575S.
10. [10] Flaker, G., Lopes, R.D., Al Khatib, S.M., et al. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol 63 (2014), 1082–1087.
11. [11] Piccini, J.P., Stevens, S.R., Lokhnygina, Y., et al. Outcomes following cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol 61 (2013), 1998–2006.
12. [12] Cappato, R., Ezekowitz, M.D., Klein, A.L., et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J 35 (2014), 3346–3355.
13. [13] Eliquis (apixaban) [package insert]. 2012, Bristol-Myers Squibb and Pfizer, Princeton, NJ and New York, NY [Issued December 2012].
14. [14] ARISTOTLE study data on file. 2011, submitted to U.S, Food and Drug Administration [unpublished data].
15. [15] Granger, C.B., Alexander, J.H., McMurray, J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365 (2011), 981–992.
16. [16] Ezekowitz, M.D., Cappato, R., Klein, A.L., et al. Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: a comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion. Am Heart J 167 (2014), 646–652.
17. [17] Lip, G.Y., Merino, J., Ezekowitz, M., et al. A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion: the EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion in atrial fibrillation study (ENSURE-AF study). Am Heart J 169 (2015), 597–604.
18. [18] Siegal, D.M., Curnutte, J.T., Connolly, S.J., et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 373:25 (2015), 2413–2424, 10.1056/NEJMoa1510991.
19. [19] Hicks, K.A., Tcheng, J.E., Bozkurt, B., et al. 2014 ACC/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: a report of the American College of Cardiology/American Heart Association Task Force on clinical data standards (Writing Committee to develop cardiovascular endpoints data standards). J Am Coll Cardiol 66 (2015), 403–469.
20. [20] Schulman, S., Kearon, C., Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3:4 (2005), 692–694.
21. [21] Kaatz, S., Ahmad, D., Spyropoulos, A.C., et al. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 13 (2015), 2119–2126.
22. [22] The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med 323:22 (1990), 1505–1511.
23. [23] Connolly, S.J., Ezekowitz, M.D., Yusuf, S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:12 (2009), 1139–1151, 10.1056/NEJMoa0905561.
24. [24] Ezekowitz, M.D., Bridgers, S.L., James, K.E., et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 327:20 (1992), 1406–1412.
25. [25] Giugliano, R.P., Ruff, C.T., Braunwald, E., et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369:22 (2013), 2093–2104, 10.1056/NEJMoa1310907.